Correlation Between ImmuCell and Innovent Biologics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ImmuCell and Innovent Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ImmuCell and Innovent Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ImmuCell and Innovent Biologics, you can compare the effects of market volatilities on ImmuCell and Innovent Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ImmuCell with a short position of Innovent Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of ImmuCell and Innovent Biologics.

Diversification Opportunities for ImmuCell and Innovent Biologics

0.18
  Correlation Coefficient

Average diversification

The 3 months correlation between ImmuCell and Innovent is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding ImmuCell and Innovent Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innovent Biologics and ImmuCell is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ImmuCell are associated (or correlated) with Innovent Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innovent Biologics has no effect on the direction of ImmuCell i.e., ImmuCell and Innovent Biologics go up and down completely randomly.

Pair Corralation between ImmuCell and Innovent Biologics

Given the investment horizon of 90 days ImmuCell is expected to under-perform the Innovent Biologics. But the stock apears to be less risky and, when comparing its historical volatility, ImmuCell is 1.21 times less risky than Innovent Biologics. The stock trades about -0.03 of its potential returns per unit of risk. The Innovent Biologics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  395.00  in Innovent Biologics on August 25, 2024 and sell it today you would earn a total of  90.00  from holding Innovent Biologics or generate 22.78% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

ImmuCell  vs.  Innovent Biologics

 Performance 
       Timeline  
ImmuCell 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in ImmuCell are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound fundamental indicators, ImmuCell is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.
Innovent Biologics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Innovent Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

ImmuCell and Innovent Biologics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ImmuCell and Innovent Biologics

The main advantage of trading using opposite ImmuCell and Innovent Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ImmuCell position performs unexpectedly, Innovent Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innovent Biologics will offset losses from the drop in Innovent Biologics' long position.
The idea behind ImmuCell and Innovent Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities